GLP-1(32-36)amide pentapeptide increases basal energy expenditure and inhibits weight gain in obese mice

Diabetes

Volumn 64, Issue 7, 2015, Pages 2409-2419

  Tomas, Eva ^a   Stanojevic, Violeta ^a   McManus, Karen ^a   Khatri, Ashok ^a   Everill, Paul ^b   Bachovchin, William W ^b   Habener, Joel F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 (32-36) AMIDE; INSULIN; PALMITIC ACID; PENTAPEPTIDE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; UNCOUPLING PROTEIN 3; GLP-1(32-36)AMIDE; GLUCAGON LIKE PEPTIDE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL METABOLIC RATE; BROWN ADIPOSE TISSUE; CALORIC INTAKE; CONTROLLED STUDY; DIABETIC OBESITY; DIET INDUCED OBESITY; DRUG IDENTIFICATION; ENERGY EXPENDITURE; ENZYME INHIBITION; FAT MASS; FATTY ACID OXIDATION; FATTY LIVER; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MASS SPECTROMETRY; MOUSE; MYOTUBE; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; THERMOGENESIS; WEIGHT GAIN; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; ENERGY METABOLISM; HUMAN; HYPERINSULINISM; LIPID DIET; METABOLISM; MOUSE MUTANT; OBESITY;

ANIMALS; BASAL METABOLISM; CELLS, CULTURED; DIET, HIGH-FAT; ENERGY METABOLISM; FATTY ACIDS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MUSCLE, SKELETAL; OBESITY; WEIGHT GAIN;

EID: 84962074642     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1708     Document Type: Article

References (45)

1. Tateya S, Kim F, Tamori Y. Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne) 2013;4:93
2. Hoehn KL, Salmon AB, Hohnen-Behrens C, et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci U S A 2009;106: 17787-17792
3. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: A unifying hypothesis. J Nutr Biochem 2008;19:491-504
4. Haas JT, Biddinger SB. Dissecting the role of insulin resistance in the metabolic syndrome. Curr Opin Lipidol 2009;20:206-210
5. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-269
6. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999;20: 876-913
7. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo. Adv Exp Med Biol 2003;524:303-312
8. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004;36:761-765
9. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 1995;58:149-156
10. Tomas E, Habener JF. Insulin-like actions of glucagon-like peptide-1: A dual receptor hypothesis. Trends Endocrinol Metab 2010;21:59-67
11. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289:H2401-H2408
12. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 2008;117:2340-2350
13. Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146:243-249
14. Ban K, Kim KH, Cho CK, et al. Glucagon-like peptide (GLP)-1(9-36)amidemediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010;151:1520-1531
15. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008;478: 136-142
16. Tomas E, Stanojevic V, Habener JF. GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res 2010;42:657-662
17. Elahi D, Egan JM, Shannon RP, et al. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring) 2008; 16:1501-1509
18. Tomas E, Stanojevic V, Wood JA, Habener JF. Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Diabetes Obes Metab 2011;13:26-33
19. Tomas E, Wood JA, Stanojevic V, Habener JF. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Regul Pept 2011;169:43-48
20. Shao W, Wang Z, Ip W, et al. GLP-1(28-36) improves b-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/b-catenin signaling in b-cells in vitro. Am J Physiol Endocrinol Metab 2013; 304:E1263-E1272
21. Liu Z, Stanojevic V, Brindamour LJ, Habener JF. GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic b-cells from glucolipotoxicity. J Endocrinol 2012;213:143-154
22. Ip W, Shao W, Chiang YT, Jin T. GLP-1-derived nonapeptide GLP-1(28-36) amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice. Am J Physiol Endocrinol Metab 2013;305: E1348-E1358
23. Tomas E, Stanojevic V, Habener JF. GLP-1-derived nonapeptide GLP-1 (28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 2011;167: 177-184
24. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009;94:1843-1852
25. Merrell K, Southwick K, Graves SW, Esplin MS, Lewis NE, Thulin CD. Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry. J Biomol Tech 2004;15:238-248
26. Kuzyk MA, Smith D, Yang J, et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009;8:1860-1877
27. Parekh PI, Petro AE, Tiller JM, Feinglos MN, Surwit RS. Reversal of dietinduced obesity and diabetes in C57BL/6J mice. Metabolism 1998;47:1089-1096
28. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-917
29. Krauss S, Zhang CY, Lowell BB. The mitochondrial uncoupling-protein homologues. Nat Rev Mol Cell Biol 2005;6:248-261
30. Echtay KS. Mitochondrial uncoupling proteins-what is their physiological role? Free Radic Biol Med 2007;43:1351-1371
31. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 2005;1:361-370
32. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006;116: 571-580
33. Rolfe DF, Brown GC. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev 1997;77:731-758
34. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagonlike peptide 1 in the anaesthetised pig. Diabetologia 2005;48:1882-1890
35. Dulloo AG, Gubler M, Montani JP, Seydoux J, Solinas G. Substrate cycling between De novo lipogenesis and lipid oxidation: A thermogenic mechanism against skeletal muscle lipotoxicity and glucolipotoxicity. Int J Obes Relat Metab Disord 2004;28(Suppl. 4):S29-S37
36. Xue B, Kahn BB. AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J Physiol 2006;574:73-83
37. Shalev A, Holst JJ, Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Invest 1997;27:10-16
38. Gu W, Lloyd DJ, Chinookswong N, et al. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice. J Pharmacol Exp Ther 2011;338:70-81
39. Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA. Alterations in energy balance following exenatide administration. Appl Physiol Nutr Metab 2012;37:893-899
40. Tan TM, Field BC, McCullough KA, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2013;62:1131-1138
41. Hansotia T, Maida A, Flock G, et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007;117:143-152
42. Brookes PS. Mitochondrial H(+) leak and ROS generation: An odd couple. Free Radic Biol Med 2005;38:12-23
43. Stanford KI, Middelbeek RJ, Townsend KL, et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest 2013;123: 215-223
44. Bézaire V, Seifert EL, Harper ME. Uncoupling protein-3: Clues in an ongoing mitochondrial mystery. FASEB J 2007;21:312-324
45. Elahi D, Angeli FS, Vakilipour A, et al. GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs. Peptides 2014;59:20-24